in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
FDA Places Import Alert on Products from Two Ranbaxy Plants
10:38 AM MDT | September 18, 2008 | Alex Scott
U.S. FDA says it has issued an import alert for officials to detain drugs reaching the U.S. border that have been made at two Indian plants owned by pharmaceutical manufacturer Ranbaxy Laboratories (Gurgaon, India). FDA says it has issued two warning letters to Ranbaxy relating to the company’s generic pharmaceutical production plants at Dewas and Paonta Sahib, India for deviating from U.S. good manufacturing practice (GMP) . FDA says it has taken the severe action to detain product made at the plants “because of the extent and...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee